TEST BANK Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 6th Edition Teri Moser Woo and Wendy L. Wright Updated Version

,TestBank Pharmacotherapeutics forAdvanced Practice Nurse Prescribers 6e Teri Moser
ss ss ss ss ss ss s ss


Woo
s




Woo 1
Pharmacotherapeutics ssfor ssAPN ssPrescribers, ss6e Ch01


Chapter 1. The Role of the Advanced Practice Nurse as Prescriber
ss ss ss ss ss ss ss ss ss ss




MULTIPLE ssCHOICE

1. Nurse sspractitioner ss prescriptive ssauthority ssis ss regulated s s by:
A. The ssNational s s Council s s of ss State ss Boards s s of s s Nursing
B. The ssU.S. s s Drug s s Enforcement s s Administration
C. The ssState ssBoard s s of s s Nursing s s for s s each s s state
D. The ssState s s Board s s of s s Pharmacy
ANS: C PTS: 1

2. The ssbenefits ssto ssthe sspatient ssof sshaving ssan ssadvanced sspractice ssregistered ssnurse
(APRN) ssprescriber ssinclude:
ss

A. Nurses ssknow ssmore ssabout sspharmacology ssthan ssother ssprescribers ssbecause ssthey
sstake ssit ssboth ssin sstheir ssbasic ssnursing ssprogram ssand ssin sstheir ssAPRN ssprogram.

B. Nurses sscare ssfor ssthe sspatient ssfrom ssa ssholistic ssapproach ssand ssinclude ssthe
sspatient ssin ssdecision-making ssregarding sstheir sscare.

C. APRNs ssare ssless s s likely ssto s s prescribe ssnarcotics s s and s s other s s controlled s s substances.
D. APRNs ssare ssable ssto ssprescribe ssindependently ssin ssall ssstates, sswhereas ssa
physician’s s s assistant s s needs s s to s s have s s a s s physician s s supervising s s their s s practice.
ANS: B PTS: 1

3. Clinical ssjudgment s s in ssprescribing s s includes:
A. Factoring ssin s s the sscost s s to s s the sspatient s s of ss the ssmedication s s prescribed
B. Always ssprescribing ssthe ss newest ss medication s s available ss for ss the ssdisease ssprocess
C. Handing s s out s s drug s s samples s s to ss poor s s patients
D. Prescribing ssall ss generic ss medications ssto ss cut s s costs
ANS: A PTS: 1

4. The ssprocess s s for ss choosing ssan s s effective ssdrug ssfor s s a ssdisorder s s includes:
A. Asking s s the s s patient s s what s s drug s s they s s think s s would s s work s s best s s for s s them
B. Consulting ssnationally ssrecognized ss guidelines ss for ssdisease ssmanagement
C. Prescribing ssmedications s s that s s are ssavailable ss as sssamples ssbefore ss writing ssa ssprescription
D. Following ssU.S. s s Drug s s Enforcement s s Administration s s guidelines s s for s s prescribing
ANS: B PTS: 1

5. Nonintentional ssnonadherence s s of ssdrug s s therapy s s may ssoccur s s due ssto:
A. Belief ss that s s medication ssdoes s s not ss work
B. Adverse ssdrug s s reactions
C. Chronic ssconditions s s that s s require ssdaily ss therapy
D. Forgetfulness s s or s s distraction
ANS: D PTS: 1

, Woo 1
Pharmacotherapeutics ssfor ssAPN Ch02
Prescribers,

Chapter 2. Review of Basic Principles of Pharmacology
ss ss ss ss ss ss ss




MULTIPLE ssCHOICE

1. A sspatient’s ssnutritional ssintake ssand sslaboratory ssresults ssreflect sshypoalbuminemia.
This ssis sscritical ssto ssprescribing ssbecause:
ss

A. Distribution ss of s s drugs s s to s s target s s tissue ssmay ss be s s affected.
B. The sssolubility s s of s s the s s drug s s will s s not s s match s s the s s site s s of s s absorption.
C. There sswill s s be ssless ss free ssdrug s s available ssto s s generate s s an s s effect.
D. Drugs ssbound s s to s s albumin ss are ssreadily s s excreted s s by ssthe sskidneys.
ANS: A PTS: 1

2. Drugs ssthat sshave ss a sssignificant ss first-pass s s effect:
A. Must s s be ssgiven s s by ssthe ss enteral s s (oral) s s route s s only
B. Bypass ssthe s s hepatic sscirculation
C. Are ssrapidly s s metabolized s s by s s the ssliver ss and s s may s s have sslittle, s s if s s any, s s desired s s action
D. Are ssconverted s s by ssthe ssliver s s to ss more ssactive ss and ssfat-soluble s s forms
ANS: C PTS: 1

3. The ssroute s s of ss excretion s s of s s a s s volatile ssdrug s s will s s likely s s be s s the:
A. Kidneys
B. Lungs
C. Bile ssand s s feces
D. Skin
ANS: B PTS: 1

4. A s s major ss disadvantage ssto s s IV s s administration ss is s s that:
A. First-pass ssmetabolism s s is sseliminated.
B. Needles ss and sssterility ss are ss required.
C. Absorption ssof ss the ssdrug ss cannot s s be ssslowed s s after s s administration.
D. It s s is s s significantly ssmore s s expensive ssthan s s other s s routes.
ANS: C PTS: 1

5. The ssnurse sspractitioner ss(NP) sschooses ssto ssgive sscephalexin ssevery ss8 sshours ssbased sson
knowledge ssof ssthe ssdrug’s:
ss

A. Propensity ss to s s go s s to ssthe sstarget s s receptor
B. Biological sshalf-life
C. Pharmacodynamics
D. Safety s s and ssside s s effects
ANS: B PTS: 1

6. Deferasirox ssis ssa sschelating ssagent ssused ssto sstreat ssiron ssoverload ssby ssbinding ssiron ssto
ss render ssit ssbiologically ssinactive. ssThis ssis ssbest sscharacterized ssas ssa(n):

, Woo 2
Pharmacotherapeutics ssfor ssAPN Ch02
Prescribers,
A. Nonreceptor ssmechanism
B. Partial ssagonist
C. Full s s agonist
D. Noncompetitive ss antagonist
ANS: A PTS: 1

7. The sspoint ssin sstime sson ssthe ssdrug ssconcentration sscurve ssthat ssindicates ssthe ssfirst
sign ssof ssa sstherapeutic sseffect ssis ssthe:
ss

A. Minimum ssadverse sseffect sslevel
B. Peak s s of s s action
C. Onset s s of s s action
D. Therapeutic ssrange
ANS: C PTS: 1

8. Phenytoin ssrequires ssthat s s a ss trough s s level ssbe s s drawn. ss Peak ssand s s trough s s levels ss are ss done:
A. When ssthe ssdrug s s has ss a sswide sstherapeutic s s range
B. When ss the ss drug s s will s s be ssadministered s s for s s a ss short s s time s s only
C. When ssthere ssis s s a sshigh s s correlation s s between ssthe ssdose ssand sssaturation s s of ss receptor s s sites
D. To ssdetermine ss if s s a ssdrug s s is s s in s s the sstherapeutic s s range
ANS: D PTS: 1

9. A sslaboratory ssresult ssindicates ssthat ssthe sspeak sslevel ssfor ssa ssdrug ssis ssabove ssthe
minimum sstoxic ssconcentration. ssThis ssmeans ssthat ssthe:
ss

A. Concentration sswill ssproduce sstherapeutic sseffects.
B. Concentration sswill ssproduce ssan ssadverse ssresponse.
C. Time ssbetween s s doses ssmust s s be ssshortened.
D. Duration s s of s s action s s of s s the s s drug s s is s s too s s long.
ANS: B PTS: 1

10. Drugs ssthat ssare ssreceptor ssagonists ssmay ssdemonstrate ss what s s property?
A. Irreversible ssbinding s s to ss the ssdrug s s receptor s s site
B. Up-regulation sswith s s chronic ssuse
C. Desensitization ssor ssdown-regulation sswith sscontinuous ssuse
D. Inverse ssrelationship ss between ssdrug ssconcentration ssand ssdrug ssaction
ANS: C PTS: 1

11. Drugs ssthat ssare ssreceptor s s antagonists, ss such ssas s s beta ssblockers, ssmay sscause:
A. Down-regulation s s of ss the ssdrug s s receptor
B. An ssexaggerated ss response ss if ssabruptly ssdiscontinued
C. Partial ssblockade ssof s s the sseffects s s of ss agonist s s drugs
D. An ssexaggerated ss response ssto sscompetitive ssdrug s s agonists
ANS: B PTS: 1